Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Enliven Therapeutics from a "sell" to a "hold," while the consensus across analysts remains a "Moderate Buy" with a $43.40 consensus price target and some firms (Mizuho, HC Wainwright) raising targets to $45 and $56.
• Shares traded around $44.25 (one‑year range $14.78–$48.53) with a $2.69 billion market cap after the company reported a quarterly EPS loss of ($0.48) that missed estimates, and analysts forecast -1.7 EPS for the current year.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

A number of other equities analysts have also recently commented on ELVN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Monday. Mizuho raised their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an "outperform" rating in a report on Wednesday, March 25th. Finally, HC Wainwright raised their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, March 26th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.40.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $44.25 on Friday. Enliven Therapeutics has a one year low of $14.78 and a one year high of $48.53. The stock's fifty day moving average is $34.90 and its 200 day moving average is $26.21. The stock has a market cap of $2.69 billion, a P/E ratio of -23.79 and a beta of 0.26.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). Analysts predict that Enliven Therapeutics will post -1.7 EPS for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the firm's stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the sale, the insider directly owned 740,188 shares of the company's stock, valued at $21,495,059.52. This trade represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard A. Heyman sold 1,230 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director directly owned 22,647 shares in the company, valued at approximately $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,230 shares of company stock valued at $473,201 over the last ninety days. 25.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP grew its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock valued at $58,982,000 after purchasing an additional 2,670,000 shares in the last quarter. TCG Crossover Management LLC purchased a new position in shares of Enliven Therapeutics during the second quarter valued at about $9,990,000. Duquesne Family Office LLC grew its position in shares of Enliven Therapeutics by 104.6% during the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company's stock valued at $19,393,000 after purchasing an additional 484,405 shares in the last quarter. Spruce Street Capital LP purchased a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $6,870,000. Finally, Polar Capital Holdings Plc increased its stake in Enliven Therapeutics by 13.5% in the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company's stock worth $54,111,000 after acquiring an additional 418,673 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.